Bioequivalence of Foslevodopa/Foscarbidopa continuous subcutaneous infusion to arm, thigh, or flank versus abdomen in healthy and advanced Parkinson’s disease individuals
The pharmacokinetics of levodopa and carbidopa demonstrated that the abdomen, arm, thigh, and flank are interchangeable sites for CSCI of LDp/CDp. There were no concerning patterns of adverse events.
Authors
- Drew S. Kern (ORCID: https://orcid.org/0000-0001-7317-3787)
- Fernando Pagán (ORCID: https://orcid.org/0000-0002-4052-156X)
- Lars Bergmann (ORCID: https://orcid.org/0000-0002-8603-8549)
- Matthew Rosebraugh (ORCID: https://orcid.org/0000-0002-8333-7738)
- Suneel Gupta (ORCID: https://orcid.org/0000-0001-7813-9940)
- Yi Rang Han (ORCID: https://orcid.org/0009-0004-1894-9019)
- Anna Jeong
- Kamran Ayub
Institutions
- Georgetown University (US)
- MedStar Georgetown University Hospital (US)
- AbbVie (United States) (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Clinical Parkinsonism & Related Disorders
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.prdoa.2025.100359
- Citations
- 1
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39